Aurinia Pharmaceuticals Q2 2024 GAAP EPS $0.01, Inline, Sales $57.200M Beat $55.055M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported Q2 2024 GAAP EPS of $0.01, meeting analyst expectations. The company also reported sales of $57.2 million, beating the $55.055 million estimate by 3.90%, and marking a 37.85% increase from the same period last year.
August 01, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aurinia Pharmaceuticals reported Q2 2024 GAAP EPS of $0.01, meeting analyst expectations. Sales of $57.2 million beat estimates by 3.90% and increased 37.85% YoY.
The company's earnings met expectations, and the sales beat estimates significantly, showing strong growth. This positive performance is likely to have a favorable short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100